8 Beaten-Down Pharmaceutical Stocks That Could Skyrocket In 2022
Pharmaceutical stocks are taking it on the chin right now. Underscoring this point, the SPDR S&P Biotech ETF, a top barometer of pharmaceutical investor sentiment, is down by a painful 22.1% year to date.
The market's "man with a hammer" attitude toward pharmaceutical stocks has arguably created some truly compelling buying opportunities for patient investors, however. Here is a brief overview of eight pharmaceutical stocks (listed alphabetically) that have fallen way too far this year, making them top buys leading into 2022.
Image source: Getty Images.
Source Fool.com
